For the first time in a single volume, distinguished experts address the complex issues - issues rarely confronted in empirical studies of patients with schizophrenia - and controversial research surrounding the assessment of negative symptoms and cognitive deficits in patients with schizophrenia.
Despite recent advances in our understanding of schizophrenia, still notably absent is consensus in assessing negative symptom treatment response. What is the most effective assessment method - given the varying methodologies and contradictory results to date? What constitutes an adequate response? Which medication - none is specifically indicated and licensed for negative symptom treatment - yields the best results? What are the indications for use of this medication? Which instrument best measures negative symptom treatment response (eight rating scales are analyzed here)? Reaching consensus among clinicians and researchers alike is even more difficult because assessment is often thwarted by extrapyramidal side effects of medications, similarities to depressive symptoms, and secondary effects of psychotic experiences.
In addition to clarifying these pressing issues, Negative Symptom and Cognitive Deficit Treatment Response in Schizophrenia also discusses ; The importance of measuring the experience of emotion versus the more traditional objectively measured symptoms in patients with schizophrenia, and how deficits in emotional experience may resist treatment - even in treatment-responsive patients.
; The family as an often overlooked source of information about negative symptom improvement or worsening, and the impact of negative symptoms on patients' relatives.
; How treatment affects social functioning and subjective experience of ""quality of life,"" and the importance of neurocognitive dysfunction in the social deficits of schizophrenia, which often persist despite significant amelioration of other symptoms.
; Specific guidelines for assessing neurocognitive treatment response. Cognitive enhancement is a major factor in improving the quality of patients' lives.
; The latest research on the neurobiology of negative symptoms, including the role of various neurotransmitter systems and brain regions in mediating negative symptom pathology. Also discussed is single vs. multiple pathophysiological processes and single treatment modality vs. distinct treatments for different aspects of negative symptoms.
; How to distinguish ""pure"" negative symptoms from deficit symptoms (i.e., those that persist for at least 1 year and are not secondary to factors such as depression, medication side effects, anxiety, delusions, and hallucinations), and which treatment is indicated for each.
Highlighted by patient vignettes, this in-depth guide will be welcomed by all clinicians who treat patients with schizophrenia and want to know and document whether their interventions ameliorate negative symptoms and cognitive dysfunction, and by all researchers who study schizophrenia, particularly those interested in clinical issues and treatment studies.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Richard S. E. Keefe, Ph.D., is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at Duke University Medical Center in Durham, North Carolina.
Joseph P. McEvoy, M.D., is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at Duke University Medical Center in Durham, North Carolina.
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Vendeur : Padilla Libros, Sevilla, SE, Espagne
Cartoné BB. Etat : New. Etat de la jaquette : Nuevo. 1. For the first time in a single volume, distinguished experts address the complex issues issues rarely confronted in empirical studies of patients with schizophrenia and controversial research surrounding the assessment of negative symptoms and cognitive deficits in patients with schizophrenia.\n\nDespite recent advances in our understanding of schizophrenia, still notably absent is consensus in assessing negative symptom treatment response, What is the most effective assessment method? What constitutes an adequate response? Which medication yields the best results? What are the indications for use of this medication? Which instrument best measures negative symptom treatment response? By clarifying the issues surrounding\nsuch complex questions, these detailed chapters bring clinicians and researchers alike closer to consensus than ever before.\n\nNegative Symplom and Cognitive Deficit Trealment Response in Schizophrenia also details other keyt opics, including the effects of treatment on social functioning and subjective experience of "quality of life," the importance of neuro-\ncognitive dysfunction, guidelines for assessing neurocognitive treatment response, the latest research on the neurobiology of negative symptoms, and ways to distinguish negative from deficit symptoms and effectively treat\nthem, Highlighted by patient vignettes, this indepth guide will be welcomed by all clinicians who treat patients with schizophrenia and want to know and document whether their interventions ameliorate negative symptoms and\ncognitive dysfunction, and by all researchers who study schizophrenia, particularly those interested in clinical issues and treatment studies.\n\n. Libros. N° de réf. du vendeur 43221
Quantité disponible : 1 disponible(s)
Vendeur : SHIMEDIA, Brooklyn, NY, Etats-Unis
Etat : New. Satisfaction Guaranteed or your money back. N° de réf. du vendeur 0880487852
Quantité disponible : 1 disponible(s)
Vendeur : Buchpark, Trebbin, Allemagne
Etat : Sehr gut. Zustand: Sehr gut | Sprache: Englisch | Produktart: Bücher | Keine Beschreibung verfügbar. N° de réf. du vendeur 2154845/2
Quantité disponible : 1 disponible(s)